| 引用本文: |
李亚楠,彭泉,冯馨瑶,康徐瑞,陈伶利,成细华.中药通过调控PGC-1α治疗非酒精性脂肪肝病的研究进展[J].湖南中医药大学学报,2023,43(7):1330-1335[点击复制] |
|
| |
|
|
| 本文已被：浏览 917次 下载 267次 |
| 中药通过调控PGC-1α治疗非酒精性脂肪肝病的研究进展 |
| 李亚楠,彭泉,冯馨瑶,康徐瑞,陈伶利,成细华 |
| (湖南中医药大学医学院, 湖南 长沙 410208;长春中医药大学针推学院, 吉林 长春 130117) |
| 摘要: |
| 非酒精性脂肪肝病（non-alcoholic fatty liver disease，NAFLD）是一种以肝细胞内脂质的异常累积为特征的代谢性疾病，包括单纯性脂肪肝（simple fatty liver，SFL）、非酒精性脂肪性肝炎（non-alcoholic steatohepatitis，NASH）及相关肝硬化和肝细胞癌。过氧化物酶体增殖物激活受体-γ共激活因子-1α（proliferator-activated receptor-γ coactivator-1α，PGC-1α）是一种转录共激活因子，能调控能量代谢，在线粒体的生物合成、糖脂代谢、机体适应性产热等过程中发挥着重要作用。NAFLD存在复杂的病因病机，临床上尚无有效治疗手段和特效药。中药擅长多靶点、多途径治疗疾病，临床已广泛用于治疗NAFLD。本文综述中药调控PGC-1α，从影响胰岛素抵抗、脂质堆积、氧化应激、炎症反应等方面改善NAFLD，为中药治疗NAFLD机制研究提供部分参考。 |
| 关键词: 非酒精性脂肪肝病 中药 PGC-1α 胰岛素抵抗 炎症 氧化应激 |
| DOI：10.3969/j.issn.1674-070X.2023.07.029 |
| 投稿时间：2022-11-02 |
| 基金项目:国家自然科学基金项目（81874375）；湖南省自然科学基金项目（2021JJ30491）；湖南省卫生健康委员会重点项目（A202303066904）；湖南省教育厅重点项目（20A376）；湖南省教育厅一般项目（19C1385）；湖南中医药大学大学生创新创业训练计划项目（2021-128，2022-153）；湖南中医药大学一流学科基础医学资助项目；湖南省国内一流培育学科中西医结合学科项目；湖南中医药大学医学院血管生物学实验室/基础医学研究所；中西医结合病原生物学湖南省重点实验室。 |
|
| Research progress on treating non-alcoholic fatty liver disease by regulating PGC-1α with Chinese medicines |
| LI Yanan,PENG Quan,FENG Xinyao,KANG Xurui,CHEN Lingli,CHENG Xihua |
| (Medical School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;School of Acupuncture-Moxibustion and Tuina, Changchun University of Chinese Medicine, Changchun, Jilin 130117, China) |
| Abstract: |
| Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by abnormal accumulation of lipids, including simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH), and associated cirrhosis and hepatocellular carcinoma. Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that regulates energy metabolism and plays an important role in processes such as mitochondrial biosynthesis, glycolipid metabolism, and adaptive thermogenesis in the body. Due to the complex etiology and pathogenesis of NAFLD, there is no effective treatment or specific drug in clinic. Chinese medicines can treat diseases through multiple targets and pathways, which has been widely used clinically for the treatment of NAFLD. This paper reviews the regulation of PGC-1α by Chinese medicines from the aspects of affecting insulin resistance, lipid accumulation, oxidative stress, and inflammatory response, providing some references for mechanism research of Chinese medicines in treating NAFLD. |
| Key words: non-alcoholic fatty liver disease Chinese medicines proliferator-activated receptor-γ coactivator-1α insulin resistance inflammation oxidative stress |
|
二维码（扫一下试试看！） |
|
|
|
|
